Slide 1: Investor Call ESMO 2025 Presentation
Investor Call ESMO 2025 Presentation
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “s
Slide 3: Developing the Next Generation of Targeted Therapies
Developing the Next Generation of Targeted Therapies
Slide 4: Broad Proprietary Pipeline
Broad Proprietary Pipeline Three lead programs in clinic with multiple programs in preclinical development , Human Registration roan Target Disease SENSES Clinical Phase 1/2 Enabling Status (Target) evaluation i Imaging Study . penaienaercene Neuroendocrine Tumors (NETs) VMT-o-NET Cohort 3: Recruite
Slide 5: Neuroendocrine Tumors: VMT-α-NET
Neuroendocrine Tumors: VMT-⍺-NET
Slide 6: Background and key takeaways
Background and key takeaways
Slide 7: Neuroendocrine Tumors: VMT-α-NET
Neuroendocrine Tumors: VMT-a-NET Targeting the somatostatin receptor to treat neuroendocrine and other cancers Neuroendocrine cells are specialized cells that secrete hormones and other bioactive substances Disease Most neuroendocrine tumors highly express somatostatin receptor type 2 (SSTR2) Overvi
Slide 8: Trial Design: [212Pb]VMT-α-NET Phase 1/2a For Neuroendocrine Tumors
Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors
Slide 9: Confidence building in compelling overall clinical profile
Confidence building in compelling overall clinical profile
Slide 10: ESMO Berlin: [212Pb]VMT-α-NET targeted alpha-particle therapy poster
02 ESvD"""~ BERLIN 025 [2’27Pb]VMT-o-NET targeted alpha-particle therapy (TAT) for advanced somatostatin receptor 2 positive (SSTR2+) neuroendocrine tumours (NETs): maturing safety and preliminary efficacy for enrollment from dose-finding cohorts 1, 2 and 3 (n=55) ‘Thorvardur Halfdanarson,' Richard
Slide 11: Study design and objectives
Study design and objectives Cohort 4 (Optional) jonnnenne--- > P"PbIVMT-a-NET ¥ n=upto8/TBD Expansion Cohort Opened in June 2025 PMP EIVMT-c-NET Gohort's RP2D mCix 4 [Pb]VMT-c-NET n=8/6mCix4 wanamneaseese A Cohort 2 H E°Pb]VMT-c-NET Recruitment Complete n=7/5mCix4 Eek Cohort 1 Intermediate doses or
Slide 12: Baseline patient characteristics
Baseline patient characteristics All patients treated by 12-SEP-2025 DCO, n = 55 Age 63 Gastroenteropancreatic (GEP)-NET 52 (95%) [years] — Pancreatic GEP-NET 19 (34%) 37-78 A — Non-pancreatic GEP-NET 33 (60%) [n, (%)] Sex | 22 (40%) Bronchial NET 24%) In, (%)] | 33 (60%) Pheochromocytoma/paragangli
Slide 13: Patient exposure and follow-up with [212Pb]VMT-α-NET
Patient exposure and follow-up with [2"*Pb]VMT-a-NET Cohort 2 Cohort 2 29 mo of follow up | <9 mo of follow up 5 mCi 5 mCi n=23 n=23 (%) (%) r All pts treated, n = 55 1 -—— Pts w2 9m flu, n = 25 —— Exposure 1 = 3 (13) 2(9) 7 (100) 12 (22) 2 = | = 3 (13) | - 3 (6) 3 | :: | = | 10 (44) | = | 10 (18) 4
Slide 14: Most common treatment-emergent adverse events (TEAEs)
Most common (2 15%) treatment-emergent adverse events (TEAEs) All patients treated, n = 55 | Grate Fatigue = + No dose-limiting toxicities (DLTs) Alopecia eee + No grade 4 or 5 adverse events Nausea Ss * No treatment-related discontinuations Diarrhoea 40% + No serious renal complications Lymphocytes
Slide 15: Blood creatinine during follow-up for all patients treated
Blood creatinine during follow-up for all patients treated All patients treated, n = 55 wo Creatinine (mg/dL) Study Week Data cutoff 12-Sept-2025. Blood creatinine increase AEs occurred in 7 pts and were Gr 1 only Six have recovered One has stabilized. Thorvardur Ragnar Halfdanarson, MD Content of t
Slide 16: Waterfall plot of best response by patient
Waterfall plot of best response by patient Cohort 2 pts with = 9m follow-up, n = 23 ae P*PPVMTONETS.0m0: Ea. = © 0 — sos) 80 80 DPR SPR PR PR PR PRR ao 5156 * 94 47 : . 0 ee 20 24 as 28 a ae 434 08 540 ah tea 643 70 s Best % change in sum of diameters from baseline 8 s s “Waterfall plot of pts enrol
Slide 17: Waterfall plot of best response by patient
Waterfall plot of best response by patient Cohort 2 pts with = 9m follow-up and with SSTR2-expression in all tumors, n = 16 Bi Shen zatinsers sre [=PPVMT-ONET S$. 0m0. Cohort 2 with 21 non SSTR2+ lesions PROMI ONET 5 Onc 8 8 8 8 8 8 8 3 3 3 3 3 3 3 m5 40 Best % change in sum of diameters from baseli
Slide 18: Swimmer plot of disposition, follow-up time and response by patient
Swimmer plot of disposition, follow-up time and response by patient Pts with 2 9m follow-up, n = 25 eas cise . . Wi Siraser sec MM Szenersonc A Potteome I cian reyes Kou tec - . we. — a x » . C) 8 16 24 32 40 48 56 64 72 80 88 96 Week Data cutoff 12-Sept-2025 . Solid segments of each bar represent t
Slide 19: Swimmer plot of disposition, follow-up time and response by patient
Swimmer plot of disposition, follow-up time and response by patient Cohort 2 pts with = 9m follow-up and with SSTR2-expression in all tumors, n = 16 eae iat - ; Pevurancrasne Ml raparsncrsonc, A eo Monn rerwsen Kon Cohort 2 with 21 non SSTR2¢ lesions M*PEIVUT-o-NET 5 Omics a - ie. — a x » . . = C) 8
Slide 20: Spider plot of tumour change over time by patient
Spider plot of tumour change over time by patient Pts with 2 9m follow-up, n = 25 Percent change in sum of diameters from baseline Percent change in sum of diameters from baseline 0 8 16 24 32 40 48 56 Data cutoff 12-Sept-2025 * One patient had a non-evaluable post baseline scan Week ‘Thorvardur Rag
Slide 21: Spider plot of tumour change over time by patient
Spider plot of tumour change over time by patient Cohort 2 pts with = 9m follow-up and with SSTR2-expression in all tumors, n = 16 Cohort 1 . q " * B*Pb]VMT-a-NET 2.5mCi Percent change in sum of diameters from baseline cn = Cohort 2 ‘°F =Pb]VMT-a-NET 5.0mCi Cohort 2 [**Pb]VMT-a-NET 5.0mCi with 21 no
Slide 22: Conclusions
Conclusions Treatment with [?'7Pb]VMT-a-NET continues to be well-tolerated among all patients treated, n = 55 - No dose-limiting toxicities (DLTs) - No grade 4 or 5 adverse events - No treatment-related discontinuations - No serious renal complications - No clinically significant treatment-related m
Slide 23: Acknowledgments
Acknowledgments The study team deeply thanks patients and their families for participating in this clinical trial This study is a multicenter clinical trial with enrollment from 11 clinical trial sites, and gratitude is extended to investigators and site personnel for their incredible partnership in
Slide 24: Next steps and concluding remarks
Next steps and concluding remarks
Slide 25: [212Pb]VMT-α-NET was well-tolerated and demonstrated appreciable anti-tumor activity
[212Pb]VMT-α-NET was well-tolerated and demonstrated appreciable anti-tumor activity
Slide 26: Key learnings for registrational study and next steps
Key learnings for registrational study and next steps
Slide 27: Upcoming data milestones
Upcoming data milestones 2025 Presentation at ESMO and Triple (anti-tumor activity data from a subset of Cohort 2 patients) VMT-o-NET (SSTR2) VMT01/02 Enrollment update for 3.0 mCi mono and combo (MC1iR) PSV359 (FAP-c) Enrollment update for 5.0 mCi 27 Early 2026 Anti-tumor activity data from nearly
Slide 28: Q & A
Q & A
Slide 29: Appendix
Appendix
Slide 30: Strong Financial Position
Strong Financial Position Funding into late 2026 Cash, cash equivalents and short-term investments as of September 30, 2025 ~$174 million Share count as of September 30, 2025 ~74.3 million Outstanding common stock warrants & options as of September 30, 2025 ~10.9 million Based on our current plans,
Slide 31: NETs Trials
NETs Trials Study NETTER-1"2 NETTER-2¢ Randomized 2:1 (+/-octreotide) Randomized 2-1 (+/-octreotide) N=229 N=226 Dose Level 4.x Q8W | 200 mci 4x Q8W | 200 mci (administered) Patient Population SSTR2+, GEP-NETs SSTR2+, GEP-NETS Prior PRRT 0% 0% Median time fromdx 3.8 years 1.9 months Performance Stat